Beating Breast Cancer With...Breast Cancer???

You heard it here FIRST [Image] 3.1 million women in the U.S. were diagnosed with breast cancer in 2022. By 2024, that number is expected to reach 4 million. The devastating disease is the most common cancer for women, save for skin cancer. Though less common, it hits men as well. Legendary KISS drummer Peter Criss was diagnosed in 2008. Global oncology spending hit $190 billion in 2022, up from $90 billion six years earlier. We spend billions every year on research, hoping to improve beyond chemo and radiation therapies, two treatments that are more than 50 years old. BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) decided to do things differently. With FDA fast-track approval, the company treats breast cancer with…breast cancer. That’s not a typo. It’s a different approach that’s yielded VERY promising results. BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) - 1-month trading range: $6.60 - 7.40 - Typical average daily volume: ~178,000 - Float: 13.38 million BriaCell Therapeutic’s Business Cancer is a genetic disease. It’s caused by changes in the genes that control how our cells grow and divide. Our cells are constantly dividing throughout our lifetime. Errors can occur: - Naturally - Damage to our DNA caused by environmental substances such as tobacco smoke or ultraviolet rays - Inherited traits Typically, our body gets rid of damaged DNA cells before they turn cancerous. That ability diminishes as we age. Cancer is not an antigen - a foreign presence like bacteria or viruses. They are simply mutated versions of your body’s cells, so our immune system fails to recognize them. BriaCell’s Bria-IMT starts with non-replicating breast cancer cells. They engineer these cells to express proteins. These cells then produce GM-CSF, which stimulates the immune response. In layman’s terms - they inject cancer-like cells into your body…except with a tweak that makes the immune system recognize it as bad. In theory, your immune system then starts to look for and destroy breast cancer cells. [The company has a cool little video that helps you visualize what’s happening.]( [jCoDx1sss-0WKkMqirdzglrFrmhWfYPUCs_R-uAh39Yz1m5kyJvZdEtbR3z0rv7RfILtVRddTbBVIxQKZYfUG3_NjuSFii4R3njk9BP1b4AoUNxFgr_JPRBVB_JiRRoXNZA3V2LvftpoJDQ-AMAvmvI] [Source: BriaCell website]( Metastatic breast cancer is especially devastating, as most patients have months to live. The company’s initial study, which earned it the FDA fast-track, showed overall survival ranging from 12-21 months, which is significant, to say the least. Additionally, the treatment shouldn’t have cross-resistance or overlapping toxicity with other treatments, meaning it can be used in conjunction/addition with/to other treatment options. Beyond the Bria-IMT and Bria-OTS, BriaCell has a deep pipeline aimed at other cancers. [rjWCJ4eMTfWGWOL4NXdggngwArsJlvnQ1-kqcWJsgvbDuUex8Bx0BkxF1lej0GMeIi-snS7b06OVD43tId1rocttPCd4gy-Z2Q8cFs9XxR9GbaUfSITvxsy6RZmYqiYED4GtuQOYd_K6-wGPuAtGUkk] [Source: BriaCell Factsheet]( Financials With no approved and marketed drugs, BriaCell generates no revenue. Its current operating income stands at -$19.2 million for the trailing 12-month period, worse than -$15.3 million for 2022 and -$7.0 million in 2021. Total cash burn sits at -$15.6 billion for the trailing 12-month period, worse than -$12.5 million for 2022 and -$7.8 million in 2021. Luckily, the company is well capitalized, with $33.5 million in cash, down from $41 million in 2022 and $57.3 million in 2021. That’s helped the company keep from issuing any new shares since 2020. Promoter Activity Promotional activity on BCTX just started to hit the wire TODAY (and this time we are helping out). Take a look at BCTX recent catalyst, here are a few notable ones: - January 23, 2023 - BriaCell investigates alleged illegal trading of public securities. The company believes certain individuals and/or companies may have engaged in manipulative and/or suspected illegal trading practices that may have artificially depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action. - February 23, 2023 - BriaCell reported positive survival data in advanced metastatic breast cancer, with 9 of 11 women remaining alive from 2021/2022 dosing, highlighting strong survival benefits. - March 30, 2023 - BriaCell announced intentions to spin out certain pre-clinical assets into a newly created ‘SpinCo. SpinCo Assets (SpinCo) includes Bria-TILsRx™ and protein kinase C delta inhibitors for multiple indications, including cancer. - [TODAY: BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR]( As a trader, I found the January press release particularly interesting. It reminds me of other OTC stocks that recently targeted ‘illegal short sellers.’ However, the biggest movement came on September 19, 2022, when volume hit 3.5 million shares as the stock plunged from $8.01 to $6.17. Oddly enough, there was no news. Shares made a low of $4.25 in December before steadily rising through February to peak at just over $8.00. Even stranger, when the company announced the FDA fast-track in April 2022, shares plunged on 17.4 million in volume from $11 to $9, which started a steady decline that brought the stock down to $4 by mid-may. Straight to the Facts It’s unusual to see a stock like this not catch any runners on news catalysts. While there haven’t been many, there’s been at least a few noteworthy ones. With a fairly small float, I suspect this stock needs a good push before it goes gangbusters. The current tight trading range makes me think it’s gearing up for a violent move. I suspect this may be coming in weeks rather than months. Always at your service, Baron Von Stocks Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Prime Tech Stocks full disclosure is to be read and fully understood before using Prime Tech Stocks website, or joining Prime Tech Stocks’ email or text list. By viewing Prime Tech Stocks website and/or reading Prime Tech Stocks email or text newsletter you are agreeing to Prime Tech Stocks full disclosure which can be read at www (dot) primetechstocks (dot) com/disclosure/ Make sure to always do your own research and due diligence on any day and swing profile brought to your attention. Prime Tech Stocks owned by Red Oak Media Group LLC, a limited liability company. Red Oak Media Group's full disclosure document can be read at www (dot) primetechstocks (dot) com/disclosure/ We do not own any shares in BCTX. We have been compensated up to Ten Thousand Dollars via bank wire transfer from a third-party Winning Media LLC for a 1 Day Marketing Program regarding BCTX with a start date of 4/17/2023 to 4/18/2023. Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](